2Firsts to Host Special Session at InterTabac on September 19

Sep.15.2025
2Firsts to Host Special Session at InterTabac on September 19
2Firsts will host a special session at the InterTabac exhibition in Dortmund on September 19, 2025, under the theme “From Change to Opportunity.” As an official media partner, 2Firsts will highlight technology, supply chain, market, and capital opportunities while fostering global dialogue.

[September 15, 2025] Global NGP media and research platform 2Firsts announced that it will host a special forum at the InterTabac exhibition in Dortmund, Germany, on the afternoon of September 19, 2025. The event, titled 2Firsts Connect @ InterTabac: From Change to Opportunity, has received strong support from the organizers and will be an integral part of the InterTabac Conference.

 

The global NGP industry and tobacco harm reduction are undergoing profound transformation. The sector urgently needs to address the “big questions” and “new trends,” inspiring fresh thinking and concrete action to support more sustainable global development and to remain true to the mission of harm reduction.

 

Against this backdrop, 2Firsts Connect @ InterTabac will focus on industry trends and opportunities, covering topics such as global e-cigarette product innovations, China’s supply chain and regulatory dynamics, the U.S. market transition, global THR strategies, and capital market perspectives. Drawing on 2Firsts’ extensive global reporting and research, the session will deliver both exclusive and forward-looking insights.

 

2Firsts to Host Special Session at InterTabac on September 19
2Firsts Connect@ InterTabac: From Change to Opportunity|Source:2Firsts

 

The session will be hosted by Alan Zhao, Co-founder & CEO of 2Firsts, together with the 2Firsts research and editorial team, including Global Editor in Chief Taco Tuinstra, who will join either on-site or via remote link. Additional distinguished guest speakers will also participate, including William Wu, Deputy Head of the Research Institute at Tianfeng Securities, with more speakers to be announced soon.

 

As an international media and research platform dedicated to the NGP industry and tobacco harm reduction, 2Firsts has successfully organized multiple seminars and industry events in Shenzhen, China, earlier this year. Its debut at InterTabac marks a new milestone for 2Firsts Events as it steps onto the global stage, further fostering international dialogue across industry, policy, science, capital, and media.

 

We warmly invite industry peers, partners, and media to join us in exploring the future of the NGP industry.

 

Event Time: September 19, 2025 | 3:00 PM – 5:30 PM

Event Venue: InterTabac Exhibition, Nowgorod Room (North Entrance), Dortmund, Germany

Contact: alan@2firsts.com

KDCA youth panel: health indicators worsen with grade level; liquid e-cigarette use tops cigarettes among 11th-grade students
KDCA youth panel: health indicators worsen with grade level; liquid e-cigarette use tops cigarettes among 11th-grade students
Korea Disease Control and Prevention Agency’s Youth Health Panel Survey (2025) Final Results Report says key adolescent health indicators worsen as students move up grade levels. By 11th grade, lifetime tobacco experience rose to 9.59%. Among 11th-grade girls, current use of liquid e-cigarettes (1.54%) surpassed conventional cigarettes (1.33%) for the first time.
Feb.10 by 2FIRSTS.ai
Australian police seize tobacco and vape products in roadside stop: goods valued at A$784,950
Australian police seize tobacco and vape products in roadside stop: goods valued at A$784,950
Australian police say that during a roadside inspection in southern New South Wales, they seized 293,200 cigarettes, 265kg of hard-pressed tobacco leaf and 2,290 vape products from a van bearing Victorian number plates, with an estimated street value of A$784,950.
Feb.26 by 2FIRSTS.ai
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
Turning Point Brands, a U.S. nicotine and tobacco-related consumer products company, reported its fiscal 2025 fourth-quarter results: quarterly revenue was $121 million, up 29% year over year; adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) was $30 million, up 14%. Net revenue from modern oral nicotine products was $41.3 million, up 266% year over year.
Mar.03 by 2FIRSTS.ai
China Boton Group Posts 2025 Revenue of RMB 1.496 Billion, With E-Cigarette Product Revenue Up 4.6%
China Boton Group Posts 2025 Revenue of RMB 1.496 Billion, With E-Cigarette Product Revenue Up 4.6%
China Boton Group reported its results for the year ended December 31, 2025. Revenue was RMB 1.496 billion, down about 9.5% from RMB 1.653 billion in 2024. Gross profit was RMB 377.1 million, with a gross margin of 25.2%, and the group recorded a net loss of RMB 1.000 billion for the year.
Mar.24 by 2FIRSTS.ai
UK vape retailer VPZ to expand manufacturing, open 40 stores in 2026
UK vape retailer VPZ to expand manufacturing, open 40 stores in 2026
UK specialist vape retailer VPZ has launched a multi-million-pound investment programme to boost domestic production capacity and tighten supply-chain controls. The plan includes adding a fifth production line, opening 40 new stores across the UK in 2026 and creating hundreds of jobs, while establishing a bonded warehouse at its Edinburgh headquarters as regulation tightens and a vaping tax is planned.
Feb.02 by 2FIRSTS.ai
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11